Cargando…
Recent advances in JAK inhibitors for the treatment of metabolic syndrome
With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around...
Autores principales: | Collotta, Debora, Franchina, Maria Paola, Carlucci, Virginia, Collino, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494544/ https://www.ncbi.nlm.nih.gov/pubmed/37701031 http://dx.doi.org/10.3389/fphar.2023.1245535 |
Ejemplares similares
-
Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery
por: Collotta, Debora, et al.
Publicado: (2023) -
Antisense oligonucleotides: a novel Frontier in pharmacological strategy
por: Collotta, D., et al.
Publicado: (2023) -
Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats
por: Patel, Nikita M., et al.
Publicado: (2023) -
Editorial: The challenges of drug repurposing in diseases related to chronic inflammation
por: Collotta, Debora, et al.
Publicado: (2023) -
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)